Connection
Vernon Holers to Drug Design
This is a "connection" page, showing publications Vernon Holers has written about Drug Design.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.188 |
|
|
|
-
Holers VM, Rohrer B, Tomlinson S. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol. 2013; 735:137-54.
Score: 0.099
-
Fridkis-Hareli M, Storek M, Mazsaroff I, Risitano AM, Lundberg AS, Horvath CJ, Holers VM. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood. 2011 Oct 27; 118(17):4705-13.
Score: 0.090